{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:22:19Z","timestamp":1783351339431,"version":"3.54.6"},"reference-count":19,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Nasolacrimal duct obstruction (NLDO) is an adverse effect of high dose radioactive iodine (RAI) therapy for thyroid carcinoma. There are currently no established preventive measures. This study assesses whether preservative free artificial tears (PFATs) can decrease the\n                      <jats:sup>131<\/jats:sup>\n                      I sodium iodide (\n                      <jats:sup>131<\/jats:sup>\n                      I) activity in the tears of patients following RAI therapy for thyroid carcinoma, and potentially serve as a preventive measure for RAI-associated NLDO.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This non-randomized prospective pilot clinical trial recruited contact-lens wearing patients undergoing RAI therapy for thyroid cancer to self-administer PFATs into the right eye for four days starting on the day of RAI ingestion. Left eyes were the controls. While wearing contacts, patients self-administered PFATs per the following\u2014Day 1: every 15 minutes for 2 hours, then every 30 minutes until bedtime, day 2: every hour for at least 12 hours, day 3: four times a day, and day 4: two times a day. Contact lenses were changed daily, and all lenses were collected one week later. Levels of\n                      <jats:sup>131<\/jats:sup>\n                      I activity were measured by a well counter, decay-corrected, and converted to units of becquerel. Statistical analyses were performed to compare the\n                      <jats:sup>131<\/jats:sup>\n                      I activities of the experimental and control eyes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sixteen eyes of eight patients treated with an average of 145.7 mCi (range 108\u2013159) of\n                      <jats:sup>131<\/jats:sup>\n                      I for papillary thyroid cancer were included. On day 1, artificial tears decreased the geometric mean\n                      <jats:sup>131<\/jats:sup>\n                      I activity by 26% in the experimental eyes (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.008). Artificial tears also decreased the geometric mean area under the curve over four days by 23% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>131<\/jats:sup>\n                      I is present in the tears following RAI therapy for thyroid carcinoma. Frequent PFATs starting on the day of RAI ingestion may decrease the level of\n                      <jats:sup>131<\/jats:sup>\n                      I in the tears. This finding could have implications for lowering the risk of NLDO. Future multi-center clinical trials are needed to determine whether the use of artificial tears after RAI therapy may decrease the risk of NLDO.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration:<\/jats:title>\n                    <jats:p>NCT04327999<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2023.0338","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T11:35:45Z","timestamp":1698924945000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears After Radioactive Iodine Treatment for Thyroid Cancer"],"prefix":"10.1177","volume":"34","author":[{"given":"Irene T.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared V.","family":"Grice","sequence":"additional","affiliation":[{"name":"Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, USA."},{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A.","family":"Bischoff","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, and Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Jessop","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behin","family":"Barahimi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Codere","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise A.","family":"Mawn","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Sobel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"issue":"2","key":"e_1_3_5_2_2","first-page":"120","article-title":"Iodine-131 for therapy of thyroid diseases","volume":"15","author":"Wyszomirska A","year":"2012","unstructured":"Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur, 2012; 15(2):120\u2013123.","journal-title":"Physical and biological basis. Nucl Med Rev Cent East Eur"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2014.29.3.233"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nic.2008.03.008"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0055"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2007.763"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.1611"},{"issue":"5","key":"e_1_3_5_8_2","first-page":"738","article-title":"Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy","volume":"42","author":"Solans R","year":"2001","unstructured":"Solans R, , Bosch JA, , Galofr\u00e9 P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med, 2001; 42(5):738\u2013743.","journal-title":"J Nucl Med"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020210"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0657"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000066"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0186"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.IOP.0000092802.75899.F8"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.IOP.0000117340.41849.81"},{"key":"e_1_3_5_15_2","first-page":"2479","article-title":"Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: Review of 19 cases","volume":"8","author":"Al-Qahtani KH","year":"2014","unstructured":"Al-Qahtani KH, , Al Asiri M, , Tunio MA, et al. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: Review of 19 cases. Clin Ophthalmol, 2014; 8:2479\u20132484.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.08.006"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492012000200005"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iop.0000179369.75569.a8"},{"issue":"8","key":"e_1_3_5_19_2","first-page":"1452","article-title":"Radioiodine secretion in tears","volume":"39","author":"Bakheet SM","year":"1998","unstructured":"Bakheet SM, , Hammami MM, , Hemidan A, et al. Radioiodine secretion in tears. J Nucl Med, 1998; 39(8):1452\u20131454.","journal-title":"J Nucl Med"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-200010000-00010"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2023.0338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2023.0338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2023.0338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:11:01Z","timestamp":1777587061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2023.0338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1089\/thy.2023.0338"],"URL":"https:\/\/doi.org\/10.1089\/thy.2023.0338","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}